BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sun H, Palcza J, Card D, Gipson A, Rosenberg R, Kryger M, Lines C, Wagner JA, Troyer MD. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea. J Clin Sleep Med 2016;12:9-17. [PMID: 26194728 DOI: 10.5664/jcsm.5382] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 James MH, Fragale JE, Aurora RN, Cooperman NA, Langleben DD, Aston-Jones G. Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer? Neuropsychopharmacology 2020;45:717-9. [PMID: 31986520 DOI: 10.1038/s41386-020-0619-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
2 Iyer SH, Aggarwal A, Warren TJ, Hallgren J, Abel PW, Simeone TA, Simeone KA. Progressive cardiorespiratory dysfunction in Kv1.1 knockout mice may provide temporal biomarkers of pending sudden unexpected death in epilepsy (SUDEP): The contribution of orexin. Epilepsia 2020;61:572-88. [PMID: 32030748 DOI: 10.1111/epi.16434] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Dujardin S, Pijpers A, Pevernagie D. Prescription Drugs Used in Insomnia. Sleep Medicine Clinics 2018;13:169-82. [DOI: 10.1016/j.jsmc.2018.03.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
4 Fonseca EM, Janes TA, Fournier S, Gargaglioni LH, Kinkead R. Orexin-A inhibits fictive air breathing responses to respiratory stimuli in the bullfrog tadpole (Lithobates catesbeianus). J Exp Biol 2021;224:jeb240804. [PMID: 33914034 DOI: 10.1242/jeb.240804] [Reference Citation Analysis]
5 Norman JL, Anderson SL. Novel class of medications, orexin receptor antagonists, in the treatment of insomnia - critical appraisal of suvorexant. Nat Sci Sleep. 2016;8:239-247. [PMID: 27471419 DOI: 10.2147/nss.s76910] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
6 Han Y, Yuan K, Zheng Y, Lu L. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders. Neurosci Bull 2020;36:432-48. [PMID: 31782044 DOI: 10.1007/s12264-019-00447-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
7 Sieminski M, Szypenbejl J, Partinen E. Orexins, Sleep, and Blood Pressure. Curr Hypertens Rep. 2018;20:79. [PMID: 29992504 DOI: 10.1007/s11906-018-0879-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
8 Janto K, Prichard JR, Pusalavidyasagar S. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics. J Clin Sleep Med 2018;14:1399-408. [PMID: 30092886 DOI: 10.5664/jcsm.7282] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
9 Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, Matzura-wolfe D, Benca RM, Krystal AD, Walsh JK, Lines C, Roth T, Michelson D. Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials. The American Journal of Geriatric Psychiatry 2017;25:791-802. [DOI: 10.1016/j.jagp.2017.03.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
10 Matsumura T, Terada J, Yoshimura C, Koshikawa K, Kinoshita T, Yahaba M, Nagashima K, Sakao S, Tatsumi K. Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience. Drug Des Devel Ther 2019;13:809-16. [PMID: 30880914 DOI: 10.2147/DDDT.S197237] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Akashiba T, Inoue Y, Uchimura N, Ohi M, Kasai T, Kawana F, Sakurai S, Takegami M, Tachikawa R, Tanigawa T, Chiba S, Chin K, Tsuiki S, Tonogi M, Nakamura H, Nakayama T, Narui K, Yagi T, Yamauchi M, Yamashiro Y, Yoshida M, Oga T, Tomita Y, Hamada S, Murase K, Mori H, Wada H, Uchiyama M, Ogawa H, Sato K, Nakata S, Mishima K, Momomura S. Sleep Apnea Syndrome (SAS) Clinical Practice Guidelines 2020. Sleep Biol Rhythms 2022;20:5-37. [DOI: 10.1007/s41105-021-00353-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Asai Y, Sano H, Miyazaki M, Iwakura M, Maeda Y, Hara M. Suvorexant (Belsomra® Tablets 10, 15, and 20 mg): Japanese Drug-Use Results Survey. Drugs R D 2019;19:27-46. [PMID: 30552562 DOI: 10.1007/s40268-018-0256-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
13 Shitara J, Kasai T, Akihiro S, Yatsu S, Matsumoto H, Suda S, Ogita M, Yanagisawa N, Fujibayashi K, Nojiri S, Nishizaki Y, Ono N, Suwa S, Daida H. Effects of suvorexant on sleep apnea in patients with heart failure: A protocol of crossover pilot trial. J Cardiol 2019;74:90-4. [PMID: 30737183 DOI: 10.1016/j.jjcc.2018.12.021] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Dujardin S, Pijpers A, Pevernagie D. Prescription Drugs Used in Insomnia. Sleep Med Clin 2020;15:133-45. [PMID: 32386689 DOI: 10.1016/j.jsmc.2020.02.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
15 Sun Y, Tisdale RK, Kilduff TS. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. Front Neurol Neurosci 2021;45:22-37. [PMID: 34052813 DOI: 10.1159/000514963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opinion on Drug Metabolism & Toxicology 2020;16:1063-78. [DOI: 10.1080/17425255.2020.1817380] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
17 Boof ML, Dingemanse J, Brunke M, Esselmann A, Heymer P, Kestermann O, Lederer K, Fietze I, Ufer M. Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease. J Sleep Res 2021;30:e13248. [PMID: 33417730 DOI: 10.1111/jsr.13248] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Schroeck JL, Ford J, Conway EL, Kurtzhalts KE, Gee ME, Vollmer KA, Mergenhagen KA. Review of Safety and Efficacy of Sleep Medicines in Older Adults. Clinical Therapeutics 2016;38:2340-72. [DOI: 10.1016/j.clinthera.2016.09.010] [Cited by in Crossref: 144] [Cited by in F6Publishing: 109] [Article Influence: 24.0] [Reference Citation Analysis]
19 Clark JW, Brian ML, Drummond SP, Hoyer D, Jacobson LH. Effects of orexin receptor antagonism on human sleep architecture: A systematic review. Sleep Medicine Reviews 2020;53:101332. [DOI: 10.1016/j.smrv.2020.101332] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
20 Reynolds AC, Adams RJ. Treatment of sleep disturbance in older adults. J Pharm Pract Res 2019;49:296-304. [DOI: 10.1002/jppr.1565] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Urrestarazu E, Iriarte J. Clinical management of sleep disturbances in Alzheimer's disease: current and emerging strategies. Nat Sci Sleep 2016;8:21-33. [PMID: 26834500 DOI: 10.2147/NSS.S76706] [Cited by in Crossref: 48] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
22 Cheng JY, Filippov G, Moline M, Zammit GK, Bsharat M, Hall N. Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: A randomized, double-blind, placebo-controlled, crossover study. J Sleep Res 2020;29:e13021. [PMID: 32187781 DOI: 10.1111/jsr.13021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
23 Suzuki K, Miyamoto M, Hirata K. Sleep disorders in the elderly: Diagnosis and management. J Gen Fam Med 2017;18:61-71. [PMID: 29263993 DOI: 10.1002/jgf2.27] [Cited by in Crossref: 60] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
24 Ufer M, Kelsh D, Schoedel KA, Dingemanse J. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem. Sleep 2021:zsab224. [PMID: 34480579 DOI: 10.1093/sleep/zsab224] [Reference Citation Analysis]
25 Boof ML, Dingemanse J, Lederer K, Fietze I, Ufer M. Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea. Sleep 2021;44:zsaa275. [PMID: 33305817 DOI: 10.1093/sleep/zsaa275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Fragale JE, James MH, Avila JA, Spaeth AM, Aurora RN, Langleben D, Aston-Jones G. The Insomnia-Addiction Positive Feedback Loop: Role of the Orexin System. Front Neurol Neurosci 2021;45:117-27. [PMID: 34052815 DOI: 10.1159/000514965] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Abad VC, Guilleminault C. Insomnia in Elderly Patients: Recommendations for Pharmacological Management. Drugs Aging 2018;35:791-817. [PMID: 30058034 DOI: 10.1007/s40266-018-0569-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 8.5] [Reference Citation Analysis]
28 Rosenberg R, Citrome L, Drake CL. Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies. Neuropsychiatr Dis Treat 2021;17:2549-66. [PMID: 34393484 DOI: 10.2147/NDT.S297504] [Reference Citation Analysis]
29 Akashiba T, Inoue Y, Uchimura N, Ohi M, Kasai T, Kawana F, Sakurai S, Takegami M, Tachikawa R, Tanigawa T, Chiba S, Chin K, Tsuiki S, Tonogi M, Nakamura H, Nakayama T, Narui K, Yagi T, Yamauchi M, Yamashiro Y, Yoshida M, Oga T, Tomita Y, Hamada S, Murase K, Mori H, Wada H, Uchiyama M, Ogawa H, Sato K, Nakata S, Mishima K, Momomura SI. Sleep Apnea Syndrome (SAS) Clinical Practice Guidelines 2020. Respir Investig 2022;60:3-32. [PMID: 34986992 DOI: 10.1016/j.resinv.2021.08.010] [Reference Citation Analysis]